KRAS antibody

Principal name

KRAS antibody

Alternative names for KRAS antibody

GTPase KRas, KRAS2, RASK2, K-Ras 2, Ki-Ras, c-K-ras, c-Ki-ras

SwissProt ID

P01116 (Human), P08644 (Rat), P32883 (Mouse), Q05147 (Xenla)

Gene ID

3845 (KRAS), 24525 (Kras)

Available reactivities

Hu (Human), Ms (Mouse), Rt (Rat), Fe (Feline)

Available hosts

Rabbit, Mouse

Available applications

Enzyme Immunoassay (E), Flow Cytometry (F), Immunocytochemistry/Immunofluorescence (ICC/IF), Immunoprecipitation (IP), Paraffin Sections (P), Western blot / Immunoblot (WB), Frozen Sections (C)

Background of KRAS antibody

This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region. [provided by RefSeq]Ras, a proto-oncogene, is a small G-protein that has 3 primary isoforms (H-Ras, N-Ras, and K-Ras) that differ in there approximately 20 C-terminal amino acids. H-Ras was first discovered as a transforming product the retrovirus Harvey murine virus and K-Ras of Kirten sarcoma virus. Ras is a heavily studied target of both academic and pharmaceutical research because of its implications in various pathways and diseases as well as being mutated in a large number of human cancers. Ras is most notably the activator of the Erk/MAPK kinase pathway as activator of Raf, as well as an activator of PI3 Kinase (PI3K). In its oncogenic, mutated state, Ras is unable to hydrolyze GTP to GDP, thus staying in an active state and activating numerous pathways including the MAPK pathway through its activation of Raf, but also others as well that include PI3 Kinase and RalGDS. One path that the pharmaceutical industry has taken to control Ras and its activity is by finding what some consider its Achilles’ heel. For its activation, Ras must localize to the plasma membrane, but interestingly, it lacks a transmembrane domain. To achieve this, Ras must first undergo a post-translational modification (PTM) known as prenylation or geranylation at its C-terminal CAAX motif. For this to take place, a controlled three step process must occur. The first step in the process is the prenylation or geranylation of the C in the CAAX motif that is initiated by the covalent attachment of farnesyl groups to the cysteine that is catalyzed by the . After this modification, the and heterodimer enzymes farnesyl transferases –aaX of the motif is proteolytically removed via Rce1 (Ras Converting Enzyme 1), a membrane associated endoprotease, by a mechanism that is still not fully understood. Finally, the C-terminal prenylcysteine is now methlylated by ICMT (Isoprenylcysteine Carboxymethyl Transferase). These drugs have yet to pass clinical trials though and there is doubt that they will ever be successful in treating tumors associated with Ras activation.

General readings

McGrath JP., et al. (1983) Nature. 304(5926): 501-506.Schubbert S., et al. (2006) Nat Genet. 38(3): 331-336.

  1. Quick-Filters:
  2. Highly Validated (1)

Items 1 to 20 of 35 total

per page
Page:
  1. 1
  2. 2

Primary Antibodies

Catalog No. Host Iso. Clone Pres. React. Applications  

KRAS antibody

HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY KRAS (RC222697, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-KRAS. Mouse IgG1 OTI4F6 Purified Hu WB
0.1 ml / €325.00
  OriGene Technologies, Inc.

TrueMAB

KRAS antibody

HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY KRAS (RC222697, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-KRAS. Mouse IgG2b OTI2C1 Purified Hu WB
0.1 ml / €325.00
  OriGene Technologies, Inc.

TrueMAB

KRAS antibody

Immunofluorescence of monoclonal antibody to KRAS on HeLa cell. [antibody concentration 10 ug/ml] Mouse IgG1 3B10-2F2 Purified Hu E, ICC/IF, WB
0.1 mg / €370.00
  Abnova Taiwan Corp.

KRAS antibody

Predicted band size: 21 kDa . Positive control: Brain tissue lysate. Recommended dilution: 1/500-2000. (Gel: 10%SDS-PAGE Lysate: 40 ug Primary antibody: 1/500 dilution Secondary antibody: Goat anti Rabbit IgG - H&L (HRP) at 1/10000 dilution Exposure time: 1 minute) Rabbit IgG Purified Hu, Ms, Rt WB
0.1 ml / €325.00
  OriGene Technologies, Inc.

KRAS antibody

HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY KRAS (RC222697, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-KRAS. Mouse IgG1 OTI1D1 Purified Hu WB
0.1 ml / €325.00
  OriGene Technologies, Inc.

TrueMAB

KRAS antibody

HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY KRAS (RC222697, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-KRAS. Mouse IgG1 OTI3B12 Purified Hu WB
0.1 ml / €325.00
  OriGene Technologies, Inc.

TrueMAB

KRAS antibody

HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY KRAS (RC222697, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-KRAS. Mouse IgG1 OTI5H6 Purified Hu WB
0.1 ml / €379.00
  OriGene Technologies, Inc.

TrueMAB

KRAS antibody

HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY KRAS (RC222697, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-KRAS. Mouse IgG1 OTI4C6 Purified Hu WB
0.1 ml / €325.00
  OriGene Technologies, Inc.

TrueMAB

KRAS antibody

HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY KRAS (RC222697, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-KRAS. Mouse IgG1 OTI2F8 Purified Hu WB
0.1 ml / €325.00
  OriGene Technologies, Inc.

TrueMAB

KRAS antibody

HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY KRAS (RC222697, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-KRAS. Mouse IgG1 OTI4B3 Purified Hu WB
0.1 ml / €325.00
  OriGene Technologies, Inc.

TrueMAB

KRAS antibody

HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY KRAS (RC222697, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-KRAS. Mouse IgG2b OTI8B4 Purified Hu WB
0.1 ml / €325.00
  OriGene Technologies, Inc.

TrueMAB

KRAS antibody

HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY KRAS (RC222697, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-KRAS. Mouse IgG1 OTI6A6 Purified Hu WB
0.1 ml / €325.00
  OriGene Technologies, Inc.

TrueMAB

KRAS antibody

HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY KRAS (RC201958, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-KRAS. Mouse IgG1 OTI2G6 Purified Hu WB
0.1 ml / €325.00
  OriGene Technologies, Inc.

TrueMAB

KRAS antibody

The Cell lysates (40ug) were resolved by SDS-PAGE, transferred to PVDF membrane and probed with anti-human KRAS antibody (1:500). Proteins were visualized using a goat anti-mouse secondary antibody conjugated to HRP and an ECL detection system.

Lane 1. : HeLa cell lysate 
Lane 2. : HepG2 cell lysate 
Lane 3. : Ramos cell lysate 
Lane 4. : A549 cell lysate 
Lane 5. : Balb/3T3 cell lysate Mouse AT2F8 Purified Hu E, F, ICC/IF, WB
0.1 ml / €310.00
  Acris Antibodies GmbH

KRAS antibody

The Cell lysates (40ug) were resolved by SDS-PAGE, transferred to PVDF membrane and probed with anti-human KRAS antibody (1:500). Proteins were visualized using a goat anti-mouse secondary antibody conjugated to HRP and an ECL detection system.

Lane 1. : HeLa cell lysate 
Lane 2. : HepG2 cell lysate 
Lane 3. : Ramos cell lysate 
Lane 4. : A549 cell lysate 
Lane 5. : Balb/3T3 cell lysate Mouse AT2F8 Purified Hu E, F, ICC/IF, WB
50 µl / €220.00
  Acris Antibodies GmbH

KRAS antibody

KRAS monoclonal antibody (M02), clone 4F3 Western Blot analysis of KRAS expression in HeLa ( Cat # L013V1 ). Mouse IgG2a 4F3 Purified Hu E, WB
0.1 mg / €370.00
  Abnova Taiwan Corp.

KRAS antibody

KRAS Mouse IgG2a 4F3 Ascites Hu E, WB
0.2 ml / €370.00
  Abnova Taiwan Corp.

KRAS antibody

KRAS Mouse IgG2a 4B6 Purified Hu E, WB
0.1 mg / €370.00
  Abnova Taiwan Corp.

KRAS antibody

KRAS Mouse IgG2a 4E2 Purified Hu E, WB
0.1 mg / €370.00
  Abnova Taiwan Corp.

KRAS antibody

KRAS Mouse IgG3 1E4-1B10 Purified Hu E, WB
0.1 mg / €370.00
  Abnova Taiwan Corp.

Items 1 to 20 of 35 total

per page
Page:
  1. 1
  2. 2
  • LinkedIn